| Literature DB >> 29552110 |
Lijuan Wang1,2, Yanchun Quan1, Yongfang Yue3, Xueyuan Heng4, Fengyuan Che1.
Abstract
Interleukin (IL)-37, a new IL-1 family member, has received increasing attention in recent years. In the past decade, it has been determined that IL-37 is expressed in various normal cells and tissues and is regulated by inflammatory stimuli and pro-cytokines via different signal transduction pathways. Recently, it has been found that IL-37 is expressed in a variety of cancers, chronic inflammatory and autoimmune disorders, and exerts anti-inflammatory effects. Moreover, a growing body of literature demonstrates that IL-37 plays a vital role in inhibiting both innate and adaptive immune responses as well as inflammatory reactions. In addition, IL-37 may prove to be a new and potentially useful target for effective cytokine therapy. Further evidence is needed to clarify in more detail the effects of IL-37 in experimental and clinical studies. Based on an extensive summary of published data, the aim of this review is to outline the current knowledge of IL-37, including the location, structure, expression, regulation and function, as well as the potential clinical applications of this cytokine.Entities:
Keywords: IL-37; clinical application; expression; function; inflammation; regulation
Year: 2018 PMID: 29552110 PMCID: PMC5840652 DOI: 10.3892/ol.2018.7982
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967